Johnson & Johnson MedTech has reported strong clinical results from its TARGET study evaluating the Monarch robotic bronchoscopy platform.
Across 679 patients and 21 global sites, clinicians successfully reached lung nodules in 98.7% of cases and achieved a diagnostic yield of 83.2%, with a safety profile comparable to non-robotic methods. The study, published in CHEST, highlights the potential of robotic-assisted bronchoscopy to improve early lung cancer detection.
Key findings linked higher diagnostic yield to bronchus signs and a history of COPD/emphysema.
Monarch’s minimally invasive platform is designed for precision targeting of small, peripheral lung nodules, potentially raising standards in pulmonary diagnostics.
Follow MEDWIRE.AI for surgical robotics and diagnostic innovation insights.
